Drug Type Bispecific antibody, Enzyme |
Synonyms- |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Hyaluronic acid modulators, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | KR | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | IL | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | ES | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | US | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | TR | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | PL | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | TW | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | PT | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | GB | 05 Aug 2022 | |
Non-Small Cell Lung Cancer | Preclinical | US | 17 Jun 2024 |